Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltartoxatug Injection Phase IV Tetanus Prophylaxis Trial
CTR20254866Phase 4Active
- Sponsor
- Trinomab Pharmaceutical
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of siltartoxatug in Tetanus, sponsored by Trinomab Pharmaceutical. Started Jan 2026; status: active.
02
Drugs
siltartoxatug
03
Conditions
Tetanus
Beyond the preview
Go deeper on CTR20254866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254866.